Zobrazeno 1 - 10
of 136
pro vyhledávání: '"Min Shan Chen"'
Autor:
Xiao‐Hui Wang, Chang‐Jun Liu, Hao‐Quan Wen, Xiao‐Hui Duan, Yu‐Qing Jiao, Yu‐Jiang Liu, Min‐Shan Chen, Kang‐Shun Zhu, Xian‐Hai Mao, Qun‐Fang Zhou
Publikováno v:
Clinical and Translational Medicine, Vol 13, Iss 3, Pp n/a-n/a (2023)
Abstract Background Targeted therapy combined with immune checkpoint inhibitors is considered a promising treatment for primary advanced hepatocellular carcinoma (HCC). Nevertheless, the difference between synchronous and asynchronous treatment of le
Externí odkaz:
https://doaj.org/article/70c9568b49344f6a849fd222544204f5
Autor:
Xiao-Hui Wang, Wen-Bin Duan, Wei Liang, Hui Li, Xiao-Yan Xie, Shao-Qiang Li, Min-Shan Chen, Ping Liang, Xian-Hai Mao, Qun-Fang Zhou
Publikováno v:
EClinicalMedicine, Vol 56, Iss , Pp 101816- (2023)
Summary: Background: The evidence of radiofrequency ablation (RFA) following transarterial chemoembolisation (TACE) combined with sorafenib for intermediate-stage recurrent hepatocellular carcinoma (RHCC) is limited. Patient responses to this treatme
Externí odkaz:
https://doaj.org/article/066958b88fe64724a5d3bcf550e809c2
Autor:
Jing-Yu Hou, Ya-ting Xiao, Jing-Bo Huang, Xin-Hua Jiang, Kai Jiang, Xun Li, Li Xu, Min-Shan Chen
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: The RESORCE trial reported that regorafenib was effective as the second-line treatment for patients with hepatocellular carcinoma (HCC) after progression on sorafenib. Real-world data are needed to assess clinical outcomes and adverse eve
Externí odkaz:
https://doaj.org/article/206d7bd527834a048b22c5c1262ca0bb
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundThe efficacy of radiofrequency ablation (RFA) for patients with early-stage recurrent hepatocellular carcinoma (HCC) with microvascular invasion (MVI) at the initial hepatectomy is limited. Our study aimed to explore whether adjuvant sorafe
Externí odkaz:
https://doaj.org/article/df2650053b6d4b7d94d9261a613077be
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
Immune checkpoint inhibitors, widely used in the treatment of malignancies, can improve the prognosis of patients, while it also can induce various immune-related adverse events, and type 1 diabetes induced by anti-programmed cell death protein-1 is
Externí odkaz:
https://doaj.org/article/ec70d9339c934d2e96d95f57141a3547
Autor:
Zhong‐Guo Zhou, Jin‐Bin Chen, Rong‐Xin Zhang, Ling Ye, Jun‐Cheng Wang, Yang‐Xun Pan, Xiao‐Hui Wang, Wen‐Xuan Li, Yao‐Jun Zhang, Li Xu, Min‐Shan Chen
Publikováno v:
Cancer Communications, Vol 40, Iss 8, Pp 355-369 (2020)
Abstract Background Hepatocellular carcinoma (HCC) is a major health problem and a primary cause of cancer‐related death worldwide. Although great advances have achieved recently by large‐scale high‐throughput analysis, the precise molecular me
Externí odkaz:
https://doaj.org/article/268a4b6db9e54bafa0ac29ae9919eefb
Autor:
Liang‐He Lu, Jie Mei, Anna Kan, Yi‐Hong Ling, Shao‐Hua Li, Wei Wei, Min‐Shan Chen, Yong‐Fa Zhang, Rong‐Ping Guo
Publikováno v:
Cancer Medicine, Vol 9, Iss 9, Pp 2997-3005 (2020)
Abstract Background and aims The optimal treatment strategy for recurrent hepatocellular carcinoma (HCC) remains unclear. Therefore, we aimed to compare the outcomes of repeat hepatic resection (RHR) and radiofrequency ablation (RFA) for recurrent HC
Externí odkaz:
https://doaj.org/article/1f06530c56dd4d38b0493f1171d45dcf
Autor:
Yu-Jie Xu MD, Zhi-Cheng Lai MD, Min-Ke He MD, Xiao-Yun Bu MD, Huan-Wei Chen MD, Yuan-Min Zhou MD, Li Xu MD, Wei Wei MD, Yao-Jun Zhang MD, Min-Shan Chen MD, Rong-Ping Guo MD, Ming Shi MD, Qi-Jiong Li MD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 20 (2021)
Purpose: Immunotherapy combined with chemotherapy have synergistic effects in multiple malignancies. We aimed to compare the efficacy and safety of toripalimab plus hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leuco
Externí odkaz:
https://doaj.org/article/cbb3d7bec5794c30ba745d6d3ade94bd
Autor:
Qing-Feng Xiang, Mei-Xiao Zhan, Yong Li, Hui Liang, Cong Hu, Yao-Ming Huang, Jing Xiao, Xu He, Yong-Jie Xin, Min-Shan Chen, Li-Gong Lu
Publikováno v:
Artificial Cells, Nanomedicine, and Biotechnology, Vol 47, Iss 1, Pp 83-89 (2019)
Sorafenib is an oral multikinase inhibitor that has become an established therapeutic approach in advanced hepatocellular carcinoma (HCC). However, the benefit of sorafenib in clinical therapy is often affected by drug resistance. Therefore, it is im
Externí odkaz:
https://doaj.org/article/3ce1e71681d14eef8d264373ee7d1d9c
Autor:
Yang-Xun Pan, Jian-Cong Chen, Ai-Ping Fang, Xiao-Hui Wang, Jin-Bin Chen, Jun-Cheng Wang, Wei He, Yi-Zhen Fu, Li Xu, Min-Shan Chen, Yao-Jun Zhang, Qi-Jiong Li, Zhong-Guo Zhou
Publikováno v:
Cancer Communications, Vol 39, Iss 1, Pp 1-11 (2019)
Abstract Background Patients with hepatocellular carcinoma (HCC) undergoing surgical resection still have a high 5-year recurrence rate (~ 60%). With the development of laparoscopic hepatectomy (LH), few studies have compared the efficacy between LH
Externí odkaz:
https://doaj.org/article/304738053b46447aa26ca4cd09e3e25e